Azetirelin

Azetirelin

SCHEMBL195158

NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CC(=O)N1

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRHR P34981 6/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Protirelin SCHEMBL10087855 0.92 TRHR (1.00) TRHR
Protirelin SCHEMBL33419 0.92 TRHR (1.00) TRHR
Protirelin SCHEMBL16091769 0.92 TRHR (1.00) TRHR
Protirelin SCHEMBL10087946 0.92 TRHR (1.00) TRHR
Taltirelin SCHEMBL13993039 0.91 TRHR (0.73) TRHR
Taltirelin SCHEMBL194528 0.91 TRHR (0.73) TRHR
Taltirelin SCHEMBL30892167 0.90 TRHR (0.72) TRHR
Taltirelin SCHEMBL2289290 0.90 TRHR (0.72) TRHR
Protirelin SCHEMBL4406163 0.89 TRHR (0.93) TRHR
Protirelin SCHEMBL1007386 0.87 TRHR (0.91) TRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117899200-A Medicament for enhancing curative effect of immunotherapy and application of medicament in treating tumors 华中科技大学 2024-04-19 CN claimed
US-20230135373-A1 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA APNIMED, INC. (DELAWARE) 2023-05-04 US claimed
WO-2021202906-A1 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA APNIMED, INC. (DELAWARE) (US) 2021-10-07 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-12624002-B2 Dimers for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-05-12 US disclosed
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 US disclosed
US-12595233-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-07 US disclosed
US-20260070894-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-03-12 US disclosed
US-12351573-B2 Compounds for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-07-08 US disclosed
WO-2002045693-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA PHARMA AG (DE) 2002-06-13 WO disclosed
CN-1076624-C Nasally administrable compositions DOTT CO LTD (JP) 2001-12-26 CN disclosed
EP-0681833-B1 Nasally administrable compositions DOTT RES LAB (JP) 2001-06-13 EP disclosed
US-5603943-A PHYSIOLOGICALLY ACTIVE SUBSTANCE HOMOGENEOUSLY DISPERSED IN AND ADSORBED ON POLYVALENT METAL CARRIER OF SPECIFIED PARTICLE SIZE DOTT RESEARCH LABORATORY (JP) 1997-02-18 US disclosed
CN-1117874-A Nasally administrable compositions DOTT RESEARCH LAB (JP) 1996-03-06 CN disclosed
EP-0681833-A2 Nasally administrable compositions DOTT RESEARCH LABORATORY (JP) 1995-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351573-B2 Compounds for use in synthesis of peptidomimetics DNPEP, NPEPPS, PAM TRHR 892/4885
US-12624002-B2 Dimers for use in synthesis of peptidomimetics GLUL, ARGLU1, ASNS TRHR 107/4885
US-20260070894-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS NPR1, NGLY1, DDAH1 TRHR 78/4885
US-12595233-B2 Thiosemicarbazates and uses thereof TST, THRB, HSPB1 TRHR 86/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT TRHR 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.